Suanfarma Appoints Pere Mañé as New CEO
Suanfarma, a global company specializing in the development, production, and commercialization of active pharmaceutical ingredients (APIs) and high-value CDMO services for the health industry, has announced the appointment of Pere Mañé Godina as its new Chief Executive Officer (CEO). This marks the beginning of a new chapter for the company, focused on industrial consolidation, sustainable innovation, and global expansion.
With a career spanning more than 30 years, Pere has held technical and strategic executive positions at leading pharmaceutical companies such as Uquifa, Boehringer Ingelheim, and Esteve Química (Esteve Group). His experience ranges from technical and operational roles to executive positions such as General Manager and Group Chief Industrial Operations Officer.
Most recently, Pere played a key role in the industrial transformation of Esteve, positioning its chemical division as a global benchmark. Under his leadership, the company was recognized as CDMO of the Year – Small Molecules at the DCAT 2025 Leadership Awards, one of the industry's most prestigious honors.
Carlos Alonso, interim CEO of Suanfarma since October 2024, commented: “We are confident that Pere’s deep sector knowledge, strategic mindset, and leadership experience will be instrumental in strengthening Suanfarma’s market position and continuing to deliver high-value solutions to our customers and partners.”
Pere Mañé Godina added: “Suanfarma has all the elements to lead the future of the industry: a solid foundation, a strong industrial platform, and a high-value international network supported by an exceptional team. I’m excited to begin this new chapter and work together to keep delivering innovative, efficient, and sustainable solutions to our clients.”
